{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:14:28Z","timestamp":1792113268882,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40263-022-00910-8","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T15:02:30Z","timestamp":1647183750000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Risdiplam: A Review in Spinal Muscular Atrophy"],"prefix":"10.1007","volume":"36","author":[{"given":"Julia","family":"Paik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,13]]},"reference":[{"issue":"3","key":"910_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","volume":"62","author":"BT Darras","year":"2015","unstructured":"Darras BT. Spinal muscular atrophies. Pediatr Clin N Am. 2015;62(3):743\u201366.","journal-title":"Pediatr Clin N Am"},{"issue":"1","key":"910_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","volume":"125","author":"L Alias","year":"2009","unstructured":"Alias L, Bernal S, Fuentes-Prior P, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet. 2009;125(1):29\u201339.","journal-title":"Hum Genet"},{"issue":"1","key":"910_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy: new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313.","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"910_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy: a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"910_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00439-017-1835-2","volume":"136","author":"CE Dominguez","year":"2017","unstructured":"Dominguez CE, Cunningham D, Chandler DS. SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities. Hum Genet. 2017;136(9):1173\u201391.","journal-title":"Hum Genet"},{"issue":"21","key":"910_CR6","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","volume":"75","author":"H Chaytow","year":"2018","unstructured":"Chaytow H, Huang YT, Gillingwater TH, et al. The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci. 2018;75(21):3877\u201394.","journal-title":"Cell Mol Life Sci"},{"key":"910_CR7","unstructured":"Genentech Inc. Evrysdi\u00ae (risdiplam) for oral solution: US prescribing information. 2021. https:\/\/www.gene.com\/. Accessed 18 Feb 2022."},{"key":"910_CR8","unstructured":"Roche Registration GmbH. Evrysdi\u00ae (risdiplam) powder for oral solution: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 18 Feb 2022."},{"issue":"1","key":"910_CR9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","volume":"8","author":"M Sivaramakrishnan","year":"2017","unstructured":"Sivaramakrishnan M, McCarthy KD, Campagne S, et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat Commun. 2017;8(1):1476.","journal-title":"Nat Commun"},{"issue":"15","key":"910_CR10","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317.","journal-title":"J Med Chem"},{"issue":"10","key":"910_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323.","journal-title":"N Engl J Med"},{"key":"910_CR12","unstructured":"Day JW, Annoussamy M, Baranello G, et al. SUNFISH part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) treatment in patients with type 2 or 3 spinal muscular atrophy (SMA) [abstract no. P.263 plus poster]. In: 25th International Annual Congress of the World Muscle Society. 2020."},{"key":"910_CR13","doi-asserted-by":"crossref","unstructured":"Chiriboga CA, Bruno C, Duong T, et al. JEWELFISH: safety, pharmacodynamic and exploratory efficacy data in non na\u00efve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam [oral presentation]. In: Cure SMA 2021. 2021.","DOI":"10.1212\/WNL.96.15_supplement.2316"},{"issue":"1","key":"910_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bcp.13786","volume":"85","author":"S Sturm","year":"2019","unstructured":"Sturm S, G\u00fcnther A, Jaber B, et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019;85(1):181\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"910_CR15","unstructured":"European Medicines Agency. Evrysdi\u00ae (risdiplam): EU public assessment report. 2021. https:\/\/www.ema.europa.eu\/. Accessed 18 Feb 2022."},{"key":"910_CR16","unstructured":"US Center for Drug Evaluation and Research. Evrysdi\u00ae (risdiplam): US summary review. 2020. https:\/\/www.accessdata.fda.gov\/. Accessed 18 Feb 2022."},{"key":"910_CR17","unstructured":"US Center for Drug Evaluation and Research. Evrysdi\u00ae (risdiplam): US clinical review. 2020. https:\/\/www.accessdata.fda.gov\/. Accessed 18 Feb 2022."},{"issue":"5","key":"910_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Beldzinska M, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427\u201335.","journal-title":"N Engl J Med"},{"key":"910_CR19","doi-asserted-by":"crossref","unstructured":"Darras BT, Masson R, Mazurkiewicz-Beldzinska M, et al. FIREFISH part 2: 24-month efficacy and safety of risdiplam in infants with type 1 spinal muscular atrophy (SMA) [poster]. In: 73rd AAN Annual Meeting. 2021.","DOI":"10.1055\/s-0041-1739636"},{"key":"910_CR20","unstructured":"Masson R, Boespflug-Tanguy O, Darras BT, et al. FIREFISH parts 1 and 2: 24-month safety and efficacy of risdiplam in type 1 SMA [poster]. In: 17th International Congress of Neuromuscular Diseases. 2021."},{"issue":"1","key":"910_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352.","journal-title":"Lancet Neurol"},{"key":"910_CR22","doi-asserted-by":"crossref","unstructured":"Oskoui M, Day JW, Deconinck N, et al. SUNFISH part 2: 24-month efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) [poster]. In: 73rd AAN Annual Meeting. 2021.","DOI":"10.1055\/s-0041-1739637"},{"issue":"2","key":"910_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"910_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207.","journal-title":"Neuromuscul Disord"},{"key":"910_CR25","unstructured":"Biogen Inc. U.S. FDA approves Biogen's SPINRAZA\u2122 (nusinersen), the first treatment for spinal muscular atrophy [media release]. 23 Dec 2016. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/us-fda-approves-biogens-spinrazatm-nusinersen-first-treatment."},{"key":"910_CR26","unstructured":"Biogen Inc. SPINRAZA\u00ae (nusinersen) approved in the European Union as first treatment for spinal muscular atrophy [media release]. 1 Jun 2017. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/spinrazar-nusinersen-approved-european-union-first-treatment."},{"key":"910_CR27","unstructured":"Biogen Inc. Spinraza\u00ae (nusinersen) injection: US prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/. Accessed 18 Feb 2022."},{"key":"910_CR28","unstructured":"European Medicines Agency. Spinraza\u00ae (nusinersen): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 18 Feb 2022."},{"issue":"7","key":"910_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/jcm9072222","volume":"9","author":"S Messina","year":"2020","unstructured":"Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9(7):222.","journal-title":"J Clin Med"},{"key":"910_CR30","unstructured":"Novartis Gene Therapies Inc. Zolgensma\u00ae (onasemnogene abeparvovec-xioi) suspension: US prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/. Accessed 18 Feb 2022."},{"key":"910_CR31","unstructured":"European Medicines Agency. Zolgensma\u00ae (onasemnogene abeparvovec): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 18 Feb 2022."},{"key":"910_CR32","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy. 2021. https:\/\/www.nice.org.uk\/. Accessed 18 Feb 2022."},{"key":"910_CR33","unstructured":"National Institute for Health and Care Excellence. Nusinersen for treating spinal muscular atrophy. 2019. https:\/\/www.nice.org.uk\/. Accessed 18 Feb 2022."},{"key":"910_CR34","unstructured":"National Institute for Health and Care Excellence. Risdiplam for treating spinal muscular atrophy. 2021. https:\/\/www.nice.org.uk\/. Accessed 18 Feb 2022."},{"issue":"1","key":"910_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monnette","year":"2021","unstructured":"Monnette A, Chen E, Hong D, et al. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16(1):36.","journal-title":"Orphanet J Rare Dis"},{"key":"910_CR36","doi-asserted-by":"crossref","unstructured":"Finkel RS, Al-Muhaizea M, Farrar MA, et al. RAINBOWFISH: a study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA) [presentation]. In: 2021 CureSMA Annual Meeting. 2021.","DOI":"10.1212\/WNL.96.15_supplement.4281"},{"key":"910_CR37","unstructured":"Servais L, Al-Muhaizea M, Farrar MA, et al. RAINBOWFISH: a study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA) [presentation]. In: WMS 2021 Virtual Congress. 2021."},{"issue":"18","key":"910_CR38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"910_CR39","first-page":"223","volume":"26","author":"RS Finkel","year":"2019","unstructured":"Finkel RS, Dabbous O, Droege M, et al. An indirect comparison of time to treatment effect in spinal muscular atrophy type 1 (SMA1) [abstract no. EPR2046]. Eur J Neurol. 2019;26(Suppl 1):223.","journal-title":"Eur J Neurol"},{"issue":"Suppl 3","key":"910_CR40","doi-asserted-by":"publisher","first-page":"S843","DOI":"10.1016\/j.jval.2019.09.2344","volume":"22","author":"M Daigl","year":"2019","unstructured":"Daigl M, Kotzeva A, Gorni K, et al. How does risdiplam compare in infantile onset spinal muscolar atrophy (SMA)? Preliminary indirect treatment comparisons based on FIREFISH part 1 data [abstract no. PRO12 plus poster]. Value Health. 2019;22(Suppl 3):S843.","journal-title":"Value Health."},{"key":"910_CR41","first-page":"1","volume":"271","author":"X Zhu","year":"2021","unstructured":"Zhu X. Comparison of nusinersen and Evrysdi in the treatment of spinal muscular atrophy. E3S Web Conf. 2021;271:1\u20134.","journal-title":"E3S Web Conf."},{"issue":"1","key":"910_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.","journal-title":"Orphanet J Rare Dis"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00910-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00910-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00910-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T01:16:42Z","timestamp":1726795002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00910-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,13]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["910"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00910-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,13]]},"assertion":[{"value":"20 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julia Paik is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}